Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05949008 · ClinicalTrials.gov registry record · Phase 4
Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo
A Phase 4 study of Obesity and NIDDM, sponsored by University of California, Los Angeles.
- Active
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05949008: Active Phase 4 study of Obesity and NIDDM, sponsored by University of California, Los Angeles.
NCT05949008 is a Phase 4 study of Obesity and NIDDM that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 150 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05949008, a Phase 4 study of Obesity and NIDDM, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Metformin is a drug used to treat patients with diabetes. The aim of this study is to examine the effect of Metformin along with a low-calorie diet on obese and/or overweight adults with an increased waist measurement. In addition, the study also aims to look at the effect of the drug vs. placebo on quality of life and physical activity.
Primary Outcome
Percent change in body weight reduction ≥5% from baseline (week 0) to week 24.
Interventions
- DRUG Placebo
- DRUG Metformin Extended Release (ER) Oral Tablet
Study Locations (1)
California
- UCLA Center for Human Nutrition - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-11-22 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 4 |
What the registry record for NCT05949008 still lists
NCT05949008 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05949008 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05949008 about?
NCT05949008 is a clinical study titled "Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo". Metformin is a drug used to treat patients with diabetes. The aim of this study is to examine the effect of Metformin along with a low-calorie diet on obese and/or overweight adults with an increased waist measurement. In addition, the study also aims to look at the effect of the drug vs. placebo on...
What is the current status of trial NCT05949008?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2023-11-22. Estimated completion is 2027-07-30.
What conditions does trial NCT05949008 study?
This clinical trial studies the following conditions: Obesity, NIDDM.
What interventions are being tested in trial NCT05949008?
The interventions under investigation include: Placebo (DRUG), Metformin Extended Release (ER) Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT05949008?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05949008 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05949008's enrollment target sits among peer trials
150 370th of 1053 higher than 668 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI